The risk factors were: ILRR receptor status (ER-positive/PR-negative/HER2-negative tumor), shorter DFI (DFI shorter than 24 months or DFI between 24 and 48 months), recurrence site (CW with or without RN and isolated RN), non-resection of ILRR, CT for the primary tumors, nodal stage at the primary tumor (N2 or N3), and no ET for the ILRR. Here, ERBB2 is linked to neoplasm.